https://www.selleckchem.com/pr....oducts/PIK-75-Hydroc
94 ± 1.9 versus placebo 0.01 ± 1.5, = 0.02, which correlated with pain reduction ( 0.001). Patients with CLBP demonstrated different phenotypes of endogenous pain modulation. In patients with reduced conditioned pain modulation, tapentadol produced long-term pain relief that coincided with reduction of signs of pain facilitation. These data indicate that the endogenous pain system may be used as a biomarker in the pharmacological treatment of CLBP, enabling an individualized, mechanism-based treatment approach. Patie
Aimer
Commentaire
Partagez
